Skip Nav Destination
Issues
1 June 2001
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
The Battle between Tumor Suppressors: Is Gene Therapy Using p16INK4a More Efficacious Than p53 for Treatment of Ovarian Carcinoma?1: Commentary re: S. C. Modesitt et al., In Vitro and In Vivo Adenovirus-mediated p53 and p16 Tumor Suppressor Therapy in Ovarian Cancer. Clin. Cancer Res., 7: 1765–1772, 2001.
Report from the FDA
Advances in Brief
Regular Articles
Clinical Trials
Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for Metastatic Prostate Cancer1
Robert T. O'Donnell; Sally J. DeNardo; Aina Yuan; Sui Shen; Carol M. Richman; Primo N. Lara; Irwin J. Griffith; Desiree S. Goldstein; David L. Kukis; Gerard S. Martinez; Gary R. Mirick; Gerald L. DeNardo; Frederick J. Meyers
Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies1
Merry L. Tetef; Timothy W. Synold; Warren Chow; Lucille Leong; Kim Margolin; Robert Morgan; James Raschko; Stephen Shibata; George Somlo; Yun Yen; Susan Groshen; Kay Johnson; Heinz-Josef Lenz; David Gandara; James H. Doroshow
A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer1
Geoffrey I. Shapiro; Jeffrey G. Supko; Angus Patterson; Cathy Lynch; Joan Lucca; Patrick F. Zacarola; Alona Muzikansky; John J. Wright; Thomas J. Lynch, Jr.; Barrett J. Rollins
A Phase I Trial of Carboxyamido-triazole and Paclitaxel for Relapsed Solid Tumors: Potential Efficacy of the Combination and Demonstration of Pharmacokinetic Interaction
Elise C. Kohn; Eddie Reed; Gisele A. Sarosy; Lori Minasian; Kenneth S. Bauer; Frieda Bostick-Bruton; Vyta Kulpa; Eichi Fuse; Anne Tompkins; Marianne Noone; Barry Goldspiel; James Pluda; William D. Figg; Lance A. Liotta
Research Articles
Molecular Oncology
Elevated Serum Levels of Type I Collagen Degradation Marker ICTP and Tissue Inhibitor of Metalloproteinase (TIMP) 1 Are Associated with Poor Prognosis in Lung Cancer
Sanna Ylisirniö; Matti Höyhtyä; Riitta Mäkitaro; Paavo Pääakkö; Juha Risteli; Vuokko L. Kinnula; Taina Turpeenniemi-Hujanen; Arja Jukkola
Diagnostic Strategy for Analytical Scanning of BRCA1 Gene by Fluorescence-assisted Mismatch Analysis Using Large, Bifluorescently Labeled Amplicons1
Enrico Ricevuto; Hagay Sobol; Dominique Stoppa-Lyonnet; Alberto Gulino; Paolo Marchetti; Corrado Ficorella; Stefano Martinotti; Tommaso Meo; Mario Tosi
Prediction of Peritoneal Micrometastasis by Peritoneal Lavaged Cytology and Reverse Transcriptase-Polymerase Chain Reaction for Matrix Metalloproteinase-7 mRNA
Yutaka Yonemura; Takashi Fujimura; Itasu Ninomiya; Byung-Sik Kim; Etsurou Bandou; Toshiharu Sawa; Kazuo Kinoshita; Yoshio Endo; Kazuo Sugiyama; Takuma Sasaki
Evaluation of the United States Food and Drug Administration-approved Scoring and Test System of HER-2 Protein Expression in Breast Cancer
Peter Birner; Georg Oberhuber; Josephine Stani; Cornelia Reithofer; Hellmut Samonigg; Hubert Hausmaninger; Ernst Kubista; Werner Kwasny; Daniela Kandioler-Eckersberger; Michael Gnant; Raimund Jakesz; the Austrian Breast & Colorectal Cancer Study Group
Clinicopathological and Molecular Evidence Indicating the Independence of Bronchioloalveolar Components from Other Subtypes of Human Peripheral Lung Adenocarcinoma
Takaomi Koga; Shuichi Hashimoto; Kenji Sugio; Ichiro Yoshino; Sepideh Mojtahedzadeh; Yoshio Matsuo; Yoshikazu Yonemitsu; Keizo Sugimachi; Katsuo Sueishi
Experimental Therapeutics, Preclinical Pharmacology
In Vitro and in Vivo Adenovirus-mediated p53 and p16 Tumor Suppressor Therapy in Ovarian Cancer1: See The Biology Behind: M. E. Murphy, The Battle between Tumor Suppressors: Is Gene Therapy Using p16INK4a More Efficacious Than p53 for Treatment of Ovarian Carcinoma? Clin. Cancer Res., 7: 1487–1489, 2001.
Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine against Ewing’s Sarcoma Cells1
Stefania Benini; Maria Cristina Manara; Nicola Baldini; Vanessa Cerisano; Massimo Serra; Mario Mercuri; Pier-Luigi Lollini; Patrizia Nanni; Piero Picci; Katia Scotlandi
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.